A New Complex Design of Fe (II) Isoleucine Dithiocarbamate as a Novel Anticancer and Antivirus against SARSCOV-2 (COVID-19).
Asian Pac J Cancer Prev
; 23(9): 3113-3123, 2022 Sep 01.
Article
in English
| MEDLINE | ID: covidwho-2205791
ABSTRACT
BACKGROUND:
This study was carried out to synthesize a new complex of Fe(II) with isoleucine dithiocarbamate ligand and to determine its potential as an anticancer and antiviral agent for SARSCOV-2.METHODS:
The synthesized complexes were then characterized by UV-vis and FT-IR spectroscopy and their melting points. The value of the conductivity of the complex compound is also determined. Anti-cancer activity was tested in vitro and molecular docking. Its potential as an antiviral against SARSCOV-2 was also carried out by molecular docking. Pharmacokinetics/ADMET properties were also carried out on the complex.RESULT:
Spectral results showed the successful synthesis of Fe(II) isoleucine dithiocarbamate complex. The complex produced UV-vis spectra at 268 and 575 nm, and the IR data at 399-599 cm-1 showed the coordination between the Fe(II) atoms with sulphur, nitrogen and oxygen of the isoleucine dithiocarbamate ligand. Fe(II) isoleucine dithiocarbamate had a cytotoxicity effect on the MCF-7 cell line (IC50 =613 µg/mL). The complex significantly caused morphological changes in the breast cancer cell line, finally leading to cell apoptosis.CONCLUSION:
Cytotoxic test of Fe(II) isoleucine dithiocarbamate showed moderate anticancer activity on MCF-7 cancer cells and showed antiviral activity against SARSCOV-2 by interfering with spike glycoprotein -ACE2 receptors, and inhibiting major proteases and 3Clpro.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Coordination Complexes
/
COVID-19 Drug Treatment
/
Antineoplastic Agents
Limits:
Humans
Language:
English
Journal:
Asian Pac J Cancer Prev
Journal subject:
Neoplasms
Year:
2022
Document Type:
Article
Affiliation country:
Apjcp.2022.23.9.3113
Similar
MEDLINE
...
LILACS
LIS